...
RXRXSMALL

Recursion Pharmaceuticals, Inc.

HealthcareBiotechnology
$3.67
$0.00(-2.65%)
52W$2.98
$7.89
FinancialsValuationvs REGN
Updated Mar 1, 12:00 AM
RSI47
RS Rating20/99
Beta2.38
Volatility86%
F-Score4/9
Mkt Cap$1.9B
DOWNTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

DOWNTREND

Recursion Pharmaceuticals, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 20), showing significant lag compared to the market leaders. Earnings growth of 60% provides fundamental context to the price action. Investors should exercise caution due to high volatility (86% annualized), which requires wider risk management.

Relative Strength
20
out of 99
Lagging
Trend Score
0/4
Minervini Criteria
DOWNTREND
Risk (Beta)
2.38
vs S&P 500
HIGH BETA
52W Position
14%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

DOWNTREND0/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$4.20
50 SMA > 100 SMA$4.62
100 SMA > 150 SMA$4.79
150 SMA > 200 SMA$4.86

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$3.73-1.72%BELOW
50 SMA$4.20-12.71%BELOW
100 SMA$4.62-20.62%BELOW
150 SMA$4.79-23.35%BELOW
200 SMA$4.86-24.54%BELOW

Price Performance

1D-2.7%
1W+7.6%
1M-17.9%
3M-20.7%
6M-24.6%
YTD-12.6%
1Y-51.1%
3Y-23.4%
52-Week Trading Range14% from low
$3.67
52W Low$2.98
52W High$7.89

Technical Indicators

RSI (14)NEUTRAL
46.7
305070
VCP ScoreCOOL
3/10
Base depth: 61.6%

Risk Profile

Beta
2.38
52W Vol
86%
ATR
$0.28
Max DD (1Y)
-55%

Volume Analysis

Today
3
50D Avg
18.15M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q1'25-28%
$-0.50
Q2'25-2%
$-0.41
Q3'25-6%
$-0.36
Q4'25+60%
$-0.21
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+85.36%
3 Years:+23.46%
TTM:+27.48%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+10.84%

Stock Price CAGR

10 Years:-14.70%
5 Years:-27.24%
3 Years:-23.35%
1 Year:-51.13%

Return on Equity

10Y Avg:-69.6%
5Y Avg:-69.6%
3Y Avg:-63.5%
Last Year:-57.0%

Key Metrics

Market Cap$1.9B
Gross Margin5.0%
Net Margin-8.6%
Piotroski F-Score4/9

More RXRX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

RXRX vs REGNREGNCNTAIMNMCLDX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 20 meansRXRX outperformed 20% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 2.38 means 138% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is RXRX in an uptrend right now?

RXRX has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.

Is RXRX overbought or oversold?

RXRX's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.

Is RXRX outperforming the market?

RXRX has a Relative Strength (RS) Rating of 20 out of 99. RXRX is currently lagging the broader market.

Where is RXRX in its 52-week range?

RXRX is trading at $3.67, which is 47% of its 52-week high ($7.89) and 14% above its 52-week low ($2.98).

How volatile is RXRX?

RXRX has a Beta of 2.38 and 52-week volatility of 86%. It's more volatile than the S&P 500 - expect bigger swings.